Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The pharmacological approaches in the treatment of type 2 diabetes (T2DM) have advanced
radically during the last decades. However, focus on long-term management of body weight,
which is an essential part of treatment success, is often lacking. Excluding surgery, there
are only a few effective treatment methods for obesity. Management of obesity is also greatly
challenged by weight regain, which is common after a successful lifestyle intervention.
Weight regain typically results in the deterioration of glucose homeostasis in T2DM. However,
understanding the pathomechanisms of weight regain and subsequent worsening of glucose
homeostasis is still insufficient. Therefore, T2DM treatment programs that target long-term
weight management have been scarce. This study aims to fill the gaps in the current knowledge
by advancing the development of treatment programs for T2DM that simultaneously head for
improved glucose metabolism and improved long-term body weight control.